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ABSTRACT
Background: Dengue shock syndrome (DSS) is the most severe form of dengue hemorrhagic fever (DHF) and has a high mortality.
There are two major pathological changes in DHF determining the severity of disease, plasma leakage and bleeding. Cytokines
released during the immune response to dengue virus have been thought to be mediators of the process.
Methods: The study involved 50 children with DSS, of whom 13 (26%) died. We investigated which clinical signs and laboratory
findings are related to mortality.
Results: We found that gastrointestinal bleeding and bilateral pleural effusion were significantly more frequent in non-survivors
than in survivors (p<0.02 and p=0.0006, respectively). Also, mean admission levels of thrombin-antithrombin complexes (TATc) and
plasminogen activator inhibitor type 1 (PAI-1), activation markers of coagulation and fibrinolysis, respectively, were significantly
higher in non-survivors (p=0.004 and p=0.0006, respectively). In regression analysis, bilateral pleural effusion and admission levels
of TATc were significantly associated with mortality (p=0.007 and p=0.048, respectively).
Conclusions: Our data provide evidence for a relationship of mortality with pleural effusion, a marker of plasma leakage, and
coagulation activation, both characteristic pathological changes in dengue shock syndrome.
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ABSTRAK
Faktor risiko kematian pada demam berdarah dengue dengan sindroma syok (DSS)
Latar belakang: DSS merupakan bentuk klinik yang paling berat dari demam berdarah dengue (DBD) dan mempunyai angka
kematian yang tinggi. Terdapat dua kelainan patologik utama pada DBD yang menentukan beratnya penyakit, yakni kebocoran
plasma dan perdarahan. Sitokine yang dilepas sewaktu terjadi respon imun virus dengue diduga merupakan mediator proses ini.
Metode: Studi dilaksanakan pada 50 penderita DSS anak, dimana 13 (26%) diantaranya meninggal. Investigasi dilakukan untuk
mencari temuan klinik dan laboratorik yang berhubungan dengan kematian.
Hasil: Perdarahan gastrointestinal dan efusi pleura bilateral secara bermakna lebih banyak ditemukan pada penderita yang
meninggal dibandingkan dengan penderita yang hidup (berturut-turut p<0,02 dan p=0,0006). Rerata kadar thrombin-antithrombin
complexes (TATc) sewaktu masuk rumah sakit dan kadar plasminogen activator inhibitor type 1 (PAI-1) juga merupakan petanda
aktivasi koagulasi dan fibrinolisis, secara bermakna (berturut-turut p=0,004 dan p=0,0006) lebih tinggi pada penderita yang
meninggal. Pada analisis regresi didapatkan bahwa efusi pleura bilateral dan kadar TATc sewaktu masuk rumah sakit berhubungan
bermakna dengan kematian (berturut-turut p=0,007 dan p=0,048).
Simpulan: Data dari studi ini membuktikan adanya hubungan antara kematian dan efusi pleura bilateral (suatu petanda kebocoran
plasma) dan aktivasi koagulasi dimana keduanya merupakan kelainan patologik khas untuk DSS.
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BACKGROUND
Dengue virus infection is an arthropod-borne disease,
caused by any of four closely related serotypes of
dengue virus, belonging to the genus Flavivirus, family
Flaviviridae: DEN-1, DEN-2, DEN-3 and DEN-4. In-
fection confers life-long homotypic, but not heterotypic,
immunity. Clinical manifestation can be asymptomatic
infection, dengue fever (DF) and dengue hemorrhagic
fever (DHF). The severity of DHF can vary from DHF I
to DHF IV. The severe forms (DHF III and IV) are also
referred to as dengue shock syndrome (DSS), cha-
racterized by shock due to leakage of plasma from
blood vessels.1
The pathogenesis of DSS is controversial. Epidemiolo-
gical studies indicate that pre-existing dengue virus anti-
bodies may predispose an individual to DHF on sub-
sequent infection with another dengue virus serotype.2-4
Other studies have demonstrated that DEN-2 and DEN-
3 are more virulent than DEN-1 and DEN-4, but all four
serotypes can cause severe or fatal disease.5-9 Epidemio-
logical observations have provided evidence that age
and race may be risk factors for DHF. DSS has been
almost confined to children10 and the age group most
severely affected was 5-9 years.11 Blacks are less
susceptible to dengue shock syndrome than whites and
Asians.3
There are two major pathological changes in DHF
determining the severity of disease, plasma leakage and
bleeding. The mechanism responsible for the increased
permeability of vascular endothelial cells and bleeding
in DHF has not been elucidated, although cytokines
released during the immune response to dengue virus
have been thought to be mediators of the process.12-14
The  mortality  rate  of  DHF  is  high,  ranging  from  2  to
10.9%,15-19 reaching 47% in patients with profound
shock.20
We conducted a prospective clinical study, to investi-
gate which clinical signs and laboratory parameters are
associated with mortality in DSS.
METHODS
This prospective study was performed in Dr. Kariadi
Hospital, the university hospital of Diponegoro Univer-
sity, Semarang, Indonesia. The research protocol was
approved by the Review Board of the Dr. Kariadi
Hospital. Written informed consent was obtained from
children’s parents or legal guardians.
Between June and November 1996, during an outbreak
of dengue in Indonesia, 50 consecutive children with the
clinical diagnosis of DSS, who were admitted to the
Paediatric Intensive Care Unit were enrolled in the
study. Only children with age 3 years were included.
The clinical diagnosis of DSS (DHF grade III and grade
IV) was finally based on the 1997 WHO criteria.(1)
Patients presenting all criteria for DHF: (i) fever or
history of acute fever 2-7 days; (ii) bleeding (mild to
severe); (iii) thrombocytopenia 100.000/mm3 or less (iv)
evidence of plasma leakage plus evidence of circulatory
failure manifested by (a) rapid and weak pulse; (b)
narrow pulse pressure (20 mmHg); (c) hypotension and
(d) cold, clammy skin and restlessness, were classified
DHF III. If profound shock with undetectable blood
pressure and pulse was present, patients were classified
as DHF IV. Decreased consciousness was based on the
Glasgow Coma Scale.21
Through clinical assessment was performed daily du-
ring hospitalization, using a medical record form. Labo-
ratory tests to support clinical management included
blood cell counts, tests for hemostasis (prothrombin
time and activated partial thromboplastin time) as well
as biochemical tests for kidney and liver functions and
electrolyte status. Thrombin-antithrombin complexes
(TATc) and plasminogen activator inhibitor type 1
(PAI-1), activation markers for coagulation and fibri-
nolysis, respectively, were also assayed. Chest x-ray and
ECG were done routinely.
Blood specimens were collected in vacutainer tubes
(Becton Dickinson, Rutherford, NJ 07417). Two ml of
blood for serological assays was collected on day of
admission and at discharge. Blood was centrifuged
1000-1500 rpm for 10 minutes, after which serum was
transferred to screw cap Eppendorf tubes and stored at -
800C, until assayed.
Full blood counts were measured with QBC, Becton
Dickinson, NJ 07417. For measurement of aPTT, PT
and TATc, venous blood (9 vol.) was drawn into
vacutainer tubes containing 0.105 M sodium citrate
(1 vol.). aPTT and PT were measured by a coagulo-
meter, KG Behnk Elektronik, and TATc levels were
determined by means of a commercially available
ELISA kit, according to the manufacturer’s instructions
(Enzygnost TAT micro, Dade Behring, Marburg
Germany); normal value <4.1mg/l. For measurement of
PAI-1, blood was collected in siliconized vacutainer
tubes containing Polybrene (Janssen Chimica, Belgium)
and EDTA (0.05%, w/v, and 10 mM, respectively, final
concentrations), to prevent in vitro complex formation.
PAI-1 was measured with sandwich ELISA kits using
specific monoclonal antibodies as described.22 All blood
samples for analysis of coagulation and fibrinolysis
were immediately immersed in melting ice and sub-
sequently centrifuged at 40C  for  20  min,  at  1600  x  g.
Plasma samples were stored at –800C, until assayed.
Normal value for PAI-1 is 30-60 ng/ml. Biochemical
tests, including liver as well as renal function tests and
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electrolytes, were measured with Auto Analyzer,
Hitachi, 7050. Normal value for serum protein were 5.9-
8.6 g/dl, and for serum albumin were 3.5-5.6 g/dl. TATc
and PAI-1 measurements were done at the Slotervaart
Hospital, Amsterdam, The Netherlands. For the trans-
port from Indonesia to The Netherlands (which last
longer than 15 hours) the samples for coagulation,
fibrinolysis, and serological assays were kept on dry ice.
The diagnosis of dengue virus infection was confirmed
by serological assays. A capture and indirect enzyme-
linked immunosorbent assay (ELISA) detected dengue
specific IgM and IgG antibodies in serum samples,
according to a previously described procedure.23
Continuous data were described in mean (SD) and no-
minal data in number (%). Nominal variables between
survivors and non-survivors were compared using x2
Test. Fisher's Exact test was performed if the number of
cells with expected frequency less than 5 were more
than 20%. Independent t-tests were done to compare
numeric variables between survivors and non-survivors.
The assumption of normality of the data was checked
before  the  t-test.  Mann-Whitney  U  tests  were  done
when the data were not normally distributed. The cut-
of-point of significance was p=0.05 with 95% confi-
dence interval. Regression analysis was done to deter-
mine factors associated with mortality. Survival time
was calculated with Kaplan-Meier curves. Log-rank test
was used for curve comparison. All statistical analyses
were performed with SPSS for Windows version 9.0.
RESULTS
Between June and November 1996, 50 children with a
clinical diagnosis of DSS, were enrolled in the study.
Thirteen patients (26%) died during follow up in the
Intensive Care Unit. The clinical diagnosis of DSS was
confirmed by serological assays in all patients, either by
an  IgM  response  or  a  fourfold  rise  in  IgG  titers.  All
antibody profiles were typical for secondary dengue
infection.
As shown in table 1, most patients were young children
who presented after about 4 days of illness. Relatively
more female patients died than males. Of the non-
survivors 4 of 13 (30.7%) were classified as DHF IV, as
compared with 3 of 37 (8.1%) survivors. The proportion
of patients with gastrointestinal and gum bleeding was
significantly higher in non-survivors than in survivors.
A clammy skin, delirium, decrease of consciousness and
bilateral pleural effusion were significantly more
frequent in non-survivors than in survivors.
Table 2 shows that the prothrombin time (a measure for
both the extrinsic and the common coagulant pathway)
was significantly longer in non-survivors than in
survivors. Also the levels of thrombin-antithrombin
complexes (TATc) and plasminogen activator inhibitor
type 1 (PAI-1), activation markers of coagulation and
fibrinolysis, respectively, were significantly higher in
non-survivors than in survivors. The levels of serum
protein were significantly lower in non-survivors than in
survivors.
In the logistic regression analysis for mortality of day of
admission levels of TATc and PAI-1, activation markers
of coagulation and fibrinolysis, respectively, we found a
significant association of TATc with mortality
(p=0.048; regression coefficient: 0.023). Such asso-
ciation was not found for PAI-1 (Table 3).
In the logistic regression analysis of albumin/protein
ratio on day of admission and bilateral pleural effusion
for mortality, a significant association was found for
bilateral pleural effusion but not for albumin/protein
ratio. The odds ratio for bilateral pleural effusion was
12.2 and p-value 0.007, implying that patients with
bilateral pleural effusion had a 12.2 times increased risk
of death (Table 3). This effect is also shown in the
cumulative survival curve of patients with and without
bilateral pleural effusion (Figure).
DISCUSSION
In  this  prospective  study  of  50  children  with  DSS,  we
found that bilateral pleural effusion and elevated TATc
concentrations were significantly associated with mor-
tality in logistic regression analysis. Bilateral pleural
effusion  indicates severe vascular leakage whereas high
TATc concentrations reflect markedly activated coa-
gulation. Our finding that bilateral pleural effusion is
associated with poor prognosis corroborates the data of
a study from Jakarta of 30 fatal cases of virologically
confirmed dengue virus infection. In that study plasma
leakage appeared to be the main cause of death, because
19 of the 30 cases (63.3%) had profound shock with
hemoconcentration.24 In an autopsy study from Thailand
of 100 children with fatal DSS plasma leakage was also
likely the main cause of death, as evidenced by >4g/dl
protein content of serous effusions in the pleural,
abdominal and pericardial cavities. Also, the mucosa,
submucosa and serosa of the gastrointestinal tract of
these children showed oedema and hemorrhage, es-
pecially in children with prolonged shock.25,26
The  admission  level  of  TATc  appeared  to  be  a  strong
predictor of mortality, indicating the pathophysiological
implication of coagulation activation. This finding is in
line with the result from an earlier study, in which we
found that high PAI-1 levels and hence activation of
coagulation were most pronounced in non-survivors,
indicating  an  ongoing  procoagulant  state.27 Studies on
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Table 1. Clinical characteristics of survivors and non-survivors in 50 patients with dengue shock syndrome
Survivors
(n=37)
Non-Survivors
(n=13)
p value
Clinical characteristics
Age (years) 6.8  2.8 6.0  2.8
Sex ratio (M/F) 20 / 17 4 / 9
DHF III/DHF IV 34 / 3 9 / 4
Days since onset of disease 4.2  0.9 4.0  1.3
Bleeding manifestations
Positive Tourniquet test 16 7 0.51
Skin bleeding 14 7 0.31
Epistaxis 7 3 0.74
Gum bleeding 0 3 <0.003
Gastrointestinal bleeding 17 11 <0.02
Hematuria 1 1 0.43
Signs of disease severity
Cold extremities 35 13 0.39
Clammy skin 3 6 0.002
Delirium 13 11 0.002
Decreased consciousness 16 11 0.01
Convulsions 2 3 0.07
Bilateral pleural effusion 2 6 0.0006
Lowest systolic blood pressure
Lowest diastolic blood pressure
92  11
59  24
83  11
45  31
Values indicated are mean SD and number
Table 2.  Laboratory tests for hemostasis and markers of plasma leakage on day of admission in survivors and non-
survivors in 50 patients with dengue shock syndrome
Survivors
(n=37)
Non-Survivors
(n=13)
p value *)
Tests for hemostasis
APTT (sec)   56.6  24.1   107.0  102.2 0.06
PT (sec)   15.3  4.7     24.2  12.0 0.001
PAI-1 (ng/ml) 285.1  491.8 1126.4  1314.6 0.0006
TATc (ng/ml)   32.2  27.3     67.5  43.3 0.004
Platelets (x109/l)   63.8  35.7     48.6  12.9 0.15
Markers of plasma leakage p value (95% CI)
Serum protein (g/l)     5.2  1.0     4.5  0.9 0.035 (0.052 - 1.335)
Serum albumin (g/l)     3.5  0.7     3.2  0.6 0.22 (-0.164 - 0.682)
Albumin/protein ratio   0.67  0.08   0.71  0.07 0.10 (-0.103 - 0.010)
Plasma sodium (mmol/l) 134.9  6.2 133.8  8.0 0.63 (-3.639 - 5.872)
Hematocrit (%)   38.3  6.4   36.4  7.4 0.39 (-2.519 - 6.227)
*  Mann-Whitney U test for differences of APTT, PT, PAI-1, TATc, and platelets; Independent t-test for serum protein, serum  albumin,
albumin/protein ratio, plasma sodium and hematocrit; APTT: activated partial thromboplastin time (control value: 31.9 1.7 sec); PT:
prothrombin time (control value: 12 0.6 sec); PAI-1: plasminogen activator inhibitor-type 1 (normal value 30-60 ng/ml); TATc:
thrombin-antithrombin complex (normal value <4.1 ng/ml).
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Table 3.  Association of markers of coagulation and fibrinolysis and of plasma leakage with mortality in 50 patients with
dengue shock syndrome
p value Exp ( )/OR
Activation markers of coagulation and fibrinolysis*)
TATc (ng/ml) 0.02 0.048 1.02
PAI-1 (100 ng/ml) 0.08 0.12 1.08
Constant -2.79 0.0002
Markers of plasma leakage
Bilateral pleural effusion 2.5 0.007 12.2
Albumin protein ratio*) 3.7 0.39 40.7
Constant -4.109 0.172
: regression coefficient; Exp. : exponent ; OR: odds ratio; TATc: thrombin-antithrombin complex; PAI-1: plasminogen activator
inhibitor type-1; *) day of admission levels
Days since admission
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Figure. Kaplan Meier survival curves of patients with bilateral pleural effusion compared with those without bilateral
pleural effusion (p=0.002). The median survival time of patients with bilateral pleural effusion was 4 days (95% CI,
1.32 - 6.68).
fatal cases demonstrated evidence of severe bleeding
followed by shock24, foci of hemorrhage in the brain28,
histological evidence of intravascular coagulation,26,29
sero-hemorrhagic effusions29 and renal impairment.30
We also found that prothrombin time was significantly
longer in non-survivors than in survivors. This suggests
that the extrinsic (tissue factor/factor VIIa) pathway
may be the main route in the activation of coagulation in
DSS.
A number of clinical signs were more frequently seen in
non-survivors than in survivors although these signs did
not qualify in the logistic regression analysis, because
these are not specific for DSS. Clammy skin was
significantly more frequent (p=0.0002) and the systolic
and diastolic blood pressures were lower in non-
survivors (Table 1). In addition, we found that delirium
and decreased consciousness were significantly more
frequent in non-survivors than in survivors (p=0.002
No bilateral pleural
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Bilateral pleural
effusion
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and p=0.010, respectively). Dengue virus subtypes 2
and 3 have been isolated from cerebrospinal fluid and
have known to be neurovirulent.31 Histological studies
from fatal DHF cases with signs of encephalopathy have
provided evidence that the brain cell is also a target cell
for dengue virus.32-36 In addition, loss of integrity of the
cerebral vascular endothelium leading to cerebral
oedema and cerebral bleeding has been observed.28,37
Conclusion our data provide evidence for a relationship
of mortality with both, plasma leakage and coagulation
activation in dengue shock syndrome. In the absence of
interventions to stop vascular leakage, close monitoring
and the use of plasma expanders to increase intravas-
cular oncotic pressure is mandatory, especially in
children with pleural effusion. In addition strategies to
control coagulation activation would be an important
area of development.
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